<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Regulation</title>
	<atom:link href="http://www.tapanray.in/tag/regulation/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Prescription In Generic Names Only, No Branded Generics</title>
		<link>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-prescription-in-generic-names-only-no-branded-generics</link>
		<comments>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/#comments</comments>
		<pubDate>Sun, 20 Aug 2023 07:24:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[branded generics]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[IMA]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[influence]]></category>
		<category><![CDATA[lack]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10812</guid>
		<description><![CDATA[The World Bank Report released on April 07, 2023 highlights that patients&#8217; Out-of-Pocket (OoP) expenses as a percentage of their total healthcare expenditure in India still accounted for as high as 50.59%. This means that patients in India generally pay for the &#8230; <a href="http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma ‘Chatbots’: For Better Stakeholder Engagement</title>
		<link>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-chatbots-for-better-stakeholder-engagement</link>
		<comments>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/#comments</comments>
		<pubDate>Mon, 29 Jul 2019 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[answers]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[assistant]]></category>
		<category><![CDATA[automated]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[Chatbots]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[functions]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Privacy]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[questions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[satisfaction]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9647</guid>
		<description><![CDATA[The critical value of meaningful interaction and engagement with individual customers &#8211; responding to their specific needs, is fast drawing attention of many businesses, for sustainable performance excellence. The same is happening in the pharma industry, as well. Creative use &#8230; <a href="http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Quality Imbroglio And ‘Culture of Bending Rules’ in India</title>
		<link>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-quality-imbroglio-and-culture-of-bending-rules-in-india</link>
		<comments>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/#comments</comments>
		<pubDate>Mon, 27 May 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bending]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[culpable]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[Culture of Bending Rules]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[letter]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[non-branded]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[quagmire]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[rules]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[warning]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9539</guid>
		<description><![CDATA[“Bottle Of Lies Exposes The Dark Side Of The Generic-Drug Boom” &#8211; re-emphasized the book, released in May 2019.  This confirms, the raging debate on the questionable quality of many generic drugs manufactured in India and involving several top domestic pharma companies, &#8230; <a href="http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Price Control And National Health Security</title>
		<link>http://www.tapanray.in/drug-price-control-and-national-health-security/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-and-national-health-security</link>
		<comments>http://www.tapanray.in/drug-price-control-and-national-health-security/#comments</comments>
		<pubDate>Mon, 25 Sep 2017 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[funded]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[irrelevant]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mentality]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[silo]]></category>
		<category><![CDATA[State]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8431</guid>
		<description><![CDATA[&#8216;Without Providing Affordable Medicines, There Can&#8217;t be Health Security&#8217;, said the Union Minister of Chemicals and Fertilizers of India, as reported on September 22, 2017. Although, the Minister made this remark while discussing Government price control on cardiac stents in &#8230; <a href="http://www.tapanray.in/drug-price-control-and-national-health-security/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-and-national-health-security/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Kickbacks And Bribes Oil Every Part of India’s Healthcare Machinery” &#8211; A National Shame?</title>
		<link>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame</link>
		<comments>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/#comments</comments>
		<pubDate>Mon, 07 Jul 2014 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Berger]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bribes]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[David]]></category>
		<category><![CDATA[Desai]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Johnson]]></category>
		<category><![CDATA[Ketan]]></category>
		<category><![CDATA[kickbacks]]></category>
		<category><![CDATA[Lucentis]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[means]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[MRs]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Nundy]]></category>
		<category><![CDATA[Parilamentary]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Samiran]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[Trade]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5584</guid>
		<description><![CDATA[“Corruption ruins the doctor-patient relationship in India” - highlights an article published in the well-reputed British Medical Journal (BMJ) on 08 May 2014. The author David Berger wrote, “Kickbacks and bribes oil every part of the country’s healthcare machinery and &#8230; <a href="http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDC Saga: Defiant Manufacturers, Sloppy Regulators and Humongous Inaction</title>
		<link>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction</link>
		<comments>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/#comments</comments>
		<pubDate>Mon, 15 Jul 2013 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[attractiveness]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[controller]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[D&C]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[DGHS]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[handsome]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[humongous]]></category>
		<category><![CDATA[inaction]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[madras]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[retraction]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[scenario]]></category>
		<category><![CDATA[slack]]></category>
		<category><![CDATA[sloppy]]></category>
		<category><![CDATA[State]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2921</guid>
		<description><![CDATA[&#8220;TO SIN BY SILENCE WHEN THEY SHOULD PROTEST MAKES COWARDS OF MEN&#8221;       &#8211; Abraham Lincoln The ghost of untested, irrational and even of bizarre kind of Fixed Dose Combination (FDC) drugs, which continue to be launched, promoted, prescribed &#8230; <a href="http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ethical Pharmaceutical Marketing Practices: &#8216;Self-Regulation&#8217;&#8230;&#8217;Voluntary Physician Payments Disclosure&#8217;&#8230;What&#8217;s next?</title>
		<link>http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next</link>
		<comments>http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/#comments</comments>
		<pubDate>Mon, 09 Nov 2009 00:30:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=730</guid>
		<description><![CDATA[Over a period of time, many stakeholders of the pharmaceutical industry and the public at large have been raising the issue of physicians being influenced in their prescription decisions by various types of payments made to them by the pharmaceutical &#8230; <a href="http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
